Glaukos Epioxa Phase 3 Extension Shows Sustained Efficacy, Favorable Safety at Three Years
MT newswire2026/10/07 21:4505:45 PM EDT, 10/07/2026 (MT Newswires) -- Glaukos (GKOS) said late Wednesday a long-term Phase 3 extension study of Epioxa, its corneal cross-linking treatment for keratoconus, showed sustained efficacy and a favorable safety profile three years after a single treatment. The study followed patients treated in Epioxa's second Phase 3 pivotal trial. Treated eyes showed a sustained 1.9-diopter (D) improvement in maximum corneal curvature from baseline, indicating corneal flattening and stabilization, the company said. No additional intervention occurred during the extension period. At year three, 29% of treated eyes gained at least two lines of best-corrected visual acuity from baseline, while 20% gained at least three lines. No serious adverse events, treatment-related adverse events or discontinuations due to adverse events were reported through three years, the medical technology company said.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
Crypto prices
More
